Survival after stroke - The impact of CHADS2 score and atrial fibrillation

International Journal of Cardiology

Volumn 141, Issue 1, 2010, Pages 18-23

  Henriksson, Karin M ^a,b   Farahmand, Bahman ^b,c   Johansson, Saga ^b,d   Åsberg, Signild ^e   Terént, Andreas ^e   Edvardsson, Nils ^d  

^a LUND UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atrial fibrillation; CHADS2 score; Mortality; Risk factor; Stroke

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BRAIN ISCHEMIA; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE REGISTRY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME VARIABLE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; SWEDEN;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; SURVIVAL RATE;

EID: 77951667741     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.122     Document Type: Article

References (23)

1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 13 (Jul 11 1994) 1449-1457
2. Hart R.G., Benavente O., McBride R., and Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 131 7 (Oct 5 1999) 492-501
3. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., and Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 22 (2001) 2864-2870
4. Wang T.J., Massaro J.M., Levy D., et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290 8 (Aug 27 2003) 1049-1056
5. Singer D.E., Albers G.W., Dalen J.E., Go A.S., Halperin J.L., and Manning W.J. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (Sep 2004) 429S-456S
6. Fang M.C., Go A.S., Chang Y., Borowsky L., Pomernacki N.K., and Singer D.E. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 51 8 (Feb 26 2008) 810-815
7. Advjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348 9028 (Sep 7 1996) 633-638
8. Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110 16 (2004) 2287-2292 [Electronic publication 004 Oct 11]
9. Welfare TNBoHa. Strokesjukvård i Sverige (2007) Stockholm
10. Stegmayr B., Asplund K., Hulter-Asberg K., et al. Stroke units in their natural habitat: can results of randomized trials be reproduced in routine clinical practice? Riks-Stroke Collaboration. Stroke 30 4 (Apr 1999) 709-714
11. Glader E.L., Stegmayr B., Norrving B., et al. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 34 8 (2003 Aug) 1970-1975
12. Rivero-Ayerza M., Scholte Op Reimer W., Lenzen M., et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J 29 13 (Jul 2008) 1618-1624
13. Kannel W.B., and Benjamin E.J. Status of the epidemiology of atrial fibrillation. Med Clin North Am 92 1 (Jan 2008) 17-40 [ix]
14. Pearce L.A., Hart R.G., and Halperin J.L. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med 109 1 (Jul 2000) 45-51
15. Go A.S., Hylek E.M., Phillips K.A., et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 102 1 (Jul 4 2000) 11-13
16. Baruch L., Gage B.F., Horrow J., et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?. Stroke 38 9 (Sep 2007) 2459-2463
17. Ionita C.C., Xavier A.R., Kirmani J.F., Dash S., Divani A.A., and Qureshi A.I. What proportion of stroke is not explained by classic risk factors?. Prev Cardiol 8 1 (Winter 2005) 41-46
18. Ay H., Benner T., Arsava E.M., et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke 38 11 (Nov 2007) 2979-2984
19. Guercini F., Acciarresi M., Agnelli G., and Paciaroni M. Cryptogenic stroke: time to determine aetiology. J Thromb Haemost 6 4 (Apr 2008) 549-554
20. Handke M., Harloff A., Olschewski M., Hetzel A., and Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 357 22 (Nov 29 2007) 2262-2268
21. Force M., Massabuau P., and Larrue V. Prevalence of atrial septal abnormalities in older patients with cryptogenic ischemic stroke or transient ischemic attack. Clin Neurol Neurosurg (Jun 3 2008)
22. Rothwell P.M. Prognostic models. Pract Neurol 8 4 (Aug 2008) 242-253
23. Coats AJ. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150